Collaborations in Diabetes Care

Collaborations in Diabetes Care

11.29.12 | By Christian Clymer

Today we've got a guest post from Dr. Murray Stewart, Senior Vice President, Metabolic Pathways and Cardiovascular, Research & Development of GlaxoSmithKline.

Diabetes care for patients is about more than the medicine. People with diabetes are asked to exercise regularly, eat moderately; and importantly, we ask them to work with a collaborative and multi-disciplinary team who can provide supportive and effective care. This collaborative approach to diabetes care however is not reserved for patients and their physicians, and needs to be a key priority for companies looking to make real progress in the fight against diabetes, because the fact is: we can't go it alone.

We have all heard the statistics. Nearly 26 million Americans have type 2 diabetes, and it shows no signs of declining. In fact, the Centers for Disease Control and Prevention (CDC) estimate that as many as one in three U.S. adults could have diabetes by 2050 if current trends continue, making effective diabetes care an urgent national, if not global, concern.

Collaboration is vital to tackling and preventing a diabetes epidemic. We have seen evidence of the success of collaborative efforts across various aspects of diabetes care. In several instances, research institutions have partnered with government agencies and companies to conduct large-scale diabetes studies that serve as the basis for how patients are treated for their diabetes and its complications. We also often see large drug companies partnering with research and academic institutions or smaller biotech companies to leverage resources and expand science to discover innovative solutions. Just this year alone, we have seen several of these partnerships, in scales large and small.

These collaborative efforts and partnerships go beyond just research and development. In Europe, the Alliance for European Diabetes Research (EURADIA) exemplifies how the force of combined resources among pharmaceutical companies and non-governmental organizations (NGOs) can bring about effective policy change. EURADIA began as an informal working group when a small group of like-minded companies and organizations came together to seek policy change, but has since grown to become an active and influential political advocate for diabetes awareness and treatment at the EU level.

Collaboration has been instrumental in the progress we have made in diabetes. The ways in which we in the industry collaborate with one another have evolved over the years as companies and organizations discover new ways and unexplored areas where we can work together to make a positive difference. As we recognize National Diabetes Month this year, we challenge the industry to think about how we can team up with others working in diabetes to identify and fill the current white space in diabetes care.

More On PhRMA — powered by PhRMApedia


Cost in Context